RxDoctor Payments Data

Jamel Reynolds, PA

Physician Assistant · Liberty, MONPI 1720605033

Payments from drug & device makers

$3,500in general payments, 2019–2025

Across 158 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$779
  • Novo Nordisk$502
  • AstraZeneca$349
  • Lilly USA, LLC$279
  • Pfizer$261
  • Sumitomo Pharma America, Inc.$214
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$3,43598%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,500 in reported general payments places this provider in the 90th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$69,453
Medicare patients
235
Services billed
2,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$63,710
OzempicSemaglutide40$45,302
TrulicityDulaglutide15$26,345
MyrbetriqMirabegron13$13,466
Atorvastatin Calcium157$1,231
Levothyroxine Sodium115$1,169
Pantoprazole Sodium98$1,151
Albuterol Sulfate HfaAlbuterol Sulfate44$1,103
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,086
Rosuvastatin Calcium101$1,008
Losartan Potassium121$933
Omeprazole52$778
Duloxetine Hcl30$697
Estradiol20$553
Lisinopril77$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$279$90,05547 claims
Novo NordiskOzempic$502$45,30240 claims
Astellas Pharma US IncMyrbetriq$65$13,46613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Liberty

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →